Literature DB >> 10415664

The role of the striatopallidal and extended amygdala systems in drug addiction.

G F Koob1.   

Abstract

Evidence suggests that the acute reinforcing actions of drugs of abuse may be mediated by specific elements of the striatopallidal and extended amygdala systems. These include the shell of the nucleus accumbens, the central nucleus of the amygdala, and the sublenticular extended amygdala. Chronic administration of drugs of abuse, including cocaine, amphetamines, nicotine, alcohol, and tetrahydrocannabinol leads to an increasing dysregulation of brain reward systems that is characterized by decreases in reward function. Withdrawal from chronic administration of cocaine, amphetamine, nicotine, alcohol, and tetrahydrocannabinol raises thresholds for brain stimulation reward. Neurochemical elements in the extended amygdala may mediate these changes, including decreases in dopamine and serotonin neurotransmission in the nucleus accumbens and increases in the brain-stress neurotransmitter, corticotropin-releasing factor, in the central nucleus of the amygdala. The combination of decreases in function of neurotransmitters involved in the positive-reinforcing properties of drugs of abuse with recruitment of brain-stress systems within the extended amygdala provides a powerful mechanism for allostatic changes in hedonic set point that can lead to the compulsive drug-seeking and drug-taking behavior characteristic of addiction.

Entities:  

Mesh:

Year:  1999        PMID: 10415664     DOI: 10.1111/j.1749-6632.1999.tb09282.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  80 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 2.  [Neuroimaging in substance abuse disorders].

Authors:  A de Mendelssohn; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

3.  Applications of a rat multiple tissue gene expression data set.

Authors:  John R Walker; Andrew I Su; David W Self; John B Hogenesch; Hilmar Lapp; Rainer Maier; Daniel Hoyer; Graeme Bilbe
Journal:  Genome Res       Date:  2004-04       Impact factor: 9.043

4.  Neuroadaptation of GABAergic transmission in the central amygdala during chronic morphine treatment.

Authors:  Michal Bajo; Marisa Roberto; Samuel G Madamba; George Robert Siggins
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

Review 5.  Stress, dysregulation of drug reward pathways, and the transition to drug dependence.

Authors:  George Koob; Mary Jeanne Kreek
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 6.  Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal.

Authors:  Andrew C Harris; Jonathan C Gewirtz
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

7.  ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration.

Authors:  Matthew F Lazenka; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2013-09-30       Impact factor: 5.250

8.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

9.  Posttranscriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol.

Authors:  Andrzej Z Pietrzykowski; Ryan M Friesen; Gilles E Martin; Sylvie I Puig; Cheryl L Nowak; Patricia M Wynne; Hava T Siegelmann; Steven N Treistman
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

Review 10.  Cocainomics: new insights into the molecular basis of cocaine addiction.

Authors:  Scott E Hemby
Journal:  J Neuroimmune Pharmacol       Date:  2010-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.